Revive Therapeutics Announces Closing of Second Tranche of Private Placement
Rhea-AI Summary
Revive Therapeutics (OTCQB: RVVTF), a specialty life sciences company, has completed the second tranche of its private placement by issuing 4,352,381 units at $0.021 per unit, raising gross proceeds of $91,400.
Each unit consists of one common share and one warrant, with warrants exercisable at $0.05 per share for 36 months. The proceeds will be used for working capital and trade payables settlement. Securities issued are subject to a four-month hold period ending January 19, 2026.
Positive
- Raised additional working capital of $91,400
- Warrants provide potential for additional future funding at $0.05 per share
Negative
- Significant dilution to existing shareholders at a low price of $0.021 per unit
- Low-priced offering indicates potential financial distress
- Funds primarily used for working capital and payables rather than growth initiatives
News Market Reaction – RVVTF
On the day this news was published, RVVTF declined 8.77%, reflecting a notable negative market reaction.
Data tracked by StockTitan Argus on the day of publication.
TORONTO, Sept. 19, 2025 (GLOBE NEWSWIRE) -- Revive Therapeutics Ltd. (“Revive” or the “Company”) (OTCQB: RVVTF) (CSE: RVV) (FRANKFURT: 31R), a specialty life sciences company dedicated to developing innovative therapeutics for critical medical needs, announces that it has closed a second tranche of its previously announced private placement (see press release of September 5, 2025) by issuing 4,352,381 units, at a price of
Each unit is comprised of one common share of the Company and one common share purchase warrant. Each warrant entitles the holder to acquire one common share at an exercise price of
The gross proceeds from the private placement offering will be used for working capital and payment of certain trade payables.
All of the securities issued are subject to a hold period of four months and one day expiring on January 19, 2026.
About Revive Therapeutics Ltd.
Revive Therapeutics is a specialty life sciences company dedicated to developing innovative therapeutics for critical medical needs. Revive strategically prioritizes its drug development pipeline to leverage FDA regulatory incentives like Emergency Use Authorization, Orphan Drug, Fast Track, and Breakthrough Therapy designations, positioning for rapid advancement and market entry. Currently, our efforts are concentrated on unlocking the vast potential of Bucillamine for infectious diseases and medical countermeasures, including the pioneering treatment of nerve agent exposure. Furthermore, Revive is vigorously advancing our Psilocybin and molecular hydrogen therapeutic programs, exploring new frontiers in medical science. For more information, visit www.ReviveThera.com.
For more information, please contact:
Michael Frank
Chief Executive Officer
Revive Therapeutics Ltd.
Tel: 1 888 901 0036
Email: mfrank@revivethera.com
Website: www.revivethera.com
Neither the Canadian Securities Exchange nor its Regulation Services Provider has reviewed or accepts responsibility for the adequacy or accuracy of this release.
Cautionary Statement
This press release contains ‘forward-looking information’ within the meaning of applicable Canadian securities legislation. These statements relate to future events or future performance. The use of any of the words “may”, “could”, “intend”, “expect”, “believe”, “will”, “projected”, “estimated” and similar expressions and statements relating to matters that are not historical facts are intended to identify forward-looking information and are based on Revive’s current belief or assumptions as to the outcome and timing of such future events. Forward looking information in this press release includes information with respect to the Company’s cannabinoids, psychedelics and infectious diseases programs. Forward-looking information is based on reasonable assumptions that have been made by Revive at the date of the information and is subject to known and unknown risks, uncertainties, and other factors that may cause actual results or events to differ materially from those anticipated in the forward-looking information. Given these risks, uncertainties and assumptions, you should not unduly rely on these forward-looking statements. The forward-looking information contained in this press release is made as of the date hereof, and Revive is not obligated to update or revise any forward-looking information, whether as a result of new information, future events or otherwise, except as required by applicable securities laws. The foregoing statements expressly qualify any forward-looking information contained herein. Reference is made to the risk factors disclosed under the heading “Risk Factors” in the Company's management's discussion and analysis for the three and nine months ended March 31, 2025 ("MD&A"), dated May 29, 2025, which is available on the Company's profile at www.sedarplus.ca.
FAQ
What is the size and price of Revive Therapeutics' (RVVTF) second tranche private placement?
What are the terms of the warrants in RVVTF's private placement?
How will Revive Therapeutics use the proceeds from this private placement?
When does the hold period expire for RVVTF's private placement securities?
What is the total potential dilution from RVVTF's private placement including warrants?
